Amag Pharmaceuticals (AMAG) 18.64 $AMAG
AMAG Pharmaceuticals, Inc. to Present at the UBS Global Healthcare Conference
GlobeNewswire - Tue May 13, 7:00AM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the UBS Global Healthcare Conference on Monday, May 19, 2014 at 3:00 p.m. ET in New York. The session will include a company presentation in which the company's business and financial outlook, strategy and growth prospects will be discussed.
AMAG Pharmaceuticals Earnings In Retrospect: Down 4.2% in the Last 18 Days (AMAG)
Comtex SmarTrend(R) - Mon May 12, 11:08AM CDT
18 days ago, on April 24th, 2014, AMAG Pharmaceuticals (NASDAQ:AMAG) reported its earnings. Analysts, on average, expected a loss of $0.07 per share on sales of $22.7 million. AMAG Pharmaceuticals actually reported a loss of $0.33 per share on sales of $20.8 million, missing EPS estimates by $0.27 and missing revenue estimates by $1.8 million. Since the company's report, shares of AMAG Pharmaceuticals have fallen from $18.05 to $17.29, representing a loss of 4.2% in the past 18 days.
22.7% Return Seen to Date on SmarTrend AMAG Pharmaceuticals Call (AMAG)
Comtex SmarTrend(R) - Tue May 06, 11:06AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 6 months, AMAG Pharmaceuticals has returned 22.74% as of today's recent price of $18.67.
Shares of AMAG Down 24.7% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 29, 9:41AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 6 months, AMAG Pharmaceuticals has returned 24.73% as of today's recent price of $18.19.
Reported and Upcoming Financial Results, Upcoming Conference Participations, and US FDA Approval - Analyst Notes on AMAG, Insys Therapeutics, Cayman, Lannett and Magellan Health Services
PR Newswire - Tue Apr 29, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Insys Therapeutics, Inc. (NASDAQ: INSY), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), Lannett Company, Inc. (NYSE: LCI) and Magellan Health Services Inc. (NASDAQ: MGLN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1741-100free.
Study Showing Effectiveness of MuGard(R) for Management of Oral Mucositis Featured in the Journal Cancer
GlobeNewswire - Mon Apr 28, 7:01AM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that the publication of data from a multi-institutional trial of MuGard has been featured in the print edition of the journal Cancer, available today. MuGard is a mucoadhesive hydrogel that forms a protective coating over the oral mucosa. The randomized, double-blind, placebo-controlled trial showed MuGard was more effective than a sham-control in significantly reducing the mouth and throat soreness associated with oral mucositis, a common and debilitating side effect of radiotherapy used to treat patients with head and neck cancer.
Wider-than-Expected Q1 Loss at AMAG - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 10:00AM CDT
AMAG Pharmaceuticals Inc.'s (AMAG) first quarter 2014 loss of 33 cents per share was wider than the Zacks Consensus Estimate of a loss of 6 cents.
AMAG Pharmaceuticals' net loss widens to USD7.1m, but revenue up 17% in Q1 2014
M2 - Fri Apr 25, 4:37AM CDT
Pharmaceutical company AMAG Pharmaceuticals (NasdaqGS:AMAG) on Thursday reported a net loss of USD7.1m (USD0.33 per share) for the first quarter ended 31 March 2014.
AMAG Announces First Quarter 2014 Financial Results
GlobeNewswire - Thu Apr 24, 6:01AM CDT
17% Total Revenue Growth, Driven by Strong Feraheme Performance
Downtrend Call Working As AMAG Pharmaceuticals Stock Falls 23.9% (AMAG)
Comtex SmarTrend(R) - Tue Apr 22, 9:13AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 6 months, AMAG Pharmaceuticals has returned 23.86% as of today's recent price of $18.40.
AMAG Pharmaceuticals, Inc. to Host Conference Call on April 24, 2014 at 8:00 a.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2014
GlobeNewswire - Tue Apr 22, 7:00AM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will report unaudited consolidated financial results for the quarter ended March 31, 2014 before the U.S. financial markets open on Thursday, April 24, 2014. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET during which management will discuss the company's first quarter financial results and provide a business update, including commercial performance and other activities.
AMAG Pharmaceuticals Announces Appointment of Jim Sulat to Its Board of Directors and the Transition of Chairman Role to Gino Santini
GlobeNewswire - Wed Apr 16, 6:49PM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced new appointments to its board of directors. Current board member, Gino Santini, has been elected, by unanimous vote, to chairman of the board of directors, effective immediately, taking over for Mike Narachi. Mr. Narachi informed the board that, after eight years of service, he has decided not to stand for re-election at this year's upcoming annual shareholder meeting in May 2014. In addition, James R. Sulat has been elected to serve as a new member of the board of directors, effective immediately.
AMAG Pharmaceuticals Has Returned 28.6% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Mon Apr 14, 4:46PM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 5 months, AMAG Pharmaceuticals has returned 28.57% as of today's recent price of $17.26.
AMAG Pharmaceuticals Shares Down 25.1% Since SmarTrend's Sell Call (AMAG)
Comtex SmarTrend(R) - Mon Apr 07, 11:06AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 5 months, AMAG Pharmaceuticals has returned 25.10% as of today's recent price of $18.10.
AMAG Pharmaceuticals, Inc. to Present at the Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 4:00PM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the 13 Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 2:20 p.m. ET in New York. The session will include a company presentation followed by a question and answer session, in which the company's business and financial outlook, strategy and growth prospects will be discussed.
AMAG Pharmaceuticals Has Returned 13.7% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Mon Mar 24, 9:27AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 5 months, AMAG Pharmaceuticals has returned 13.72% as of today's recent price of $20.85.
Concise Analysis of the International Intravenous (IV) Iron Drugs Industry
M2 - Tue Mar 11, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k8bxct/intravenous_iv) has announced the addition of the "Concise Analysis of the International Intravenous (IV) Iron Drugs Industry" report to their offering. This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 20 companies including many key and niche players such as: - Actavis, Inc. - AMAG Pharmaceuticals, Inc. - Fresenius Medical Care AG & Co. - KGaA Galenica Ltd. - Vifor Pharma Ltd. - Luitpold Pharmaceuticals, Inc. - American Regent, Inc. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview & Trends 3. Regulatory Overview 4. Overview Of Intravenous (Iv) Iron Drugs 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 20 (including Divisions/Subsidiaries - 22) - The United States (
- Japan (2) - Europe (4) - Germany (1) - Rest of Europe (3) - Asia-Pacific (Excluding Japan) ( For more information visit http://www.researchandmarkets.com/research/k8...avenous_iv
Stock Price Updates, Appointment, and Financial Results - Analyst Notes on Regeneron, DENTSPLY, AMAG, Cadence, and ArthroCare
PR Newswire - Thu Mar 06, 10:50AM CST
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), DENTSPLY International Inc. (NASDAQ: XRAY), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Cadence Pharmaceuticals Inc. (NASDAQ: CADX), and ArthroCare Corporation (NASDAQ: ARTC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
AMAG Pharmaceuticals, Inc. to Present at the UBS Global Healthcare Conference
GlobeNewswire - Tue May 13, 7:00AM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the UBS Global Healthcare Conference on Monday, May 19, 2014 at 3:00 p.m. ET in New York. The session will include a company presentation in which the company's business and financial outlook, strategy and growth prospects will be discussed.
AMAG Pharmaceuticals Earnings In Retrospect: Down 4.2% in the Last 18 Days (AMAG)
Comtex SmarTrend(R) - Mon May 12, 11:08AM CDT
18 days ago, on April 24th, 2014, AMAG Pharmaceuticals (NASDAQ:AMAG) reported its earnings. Analysts, on average, expected a loss of $0.07 per share on sales of $22.7 million. AMAG Pharmaceuticals actually reported a loss of $0.33 per share on sales of $20.8 million, missing EPS estimates by $0.27 and missing revenue estimates by $1.8 million. Since the company's report, shares of AMAG Pharmaceuticals have fallen from $18.05 to $17.29, representing a loss of 4.2% in the past 18 days.
22.7% Return Seen to Date on SmarTrend AMAG Pharmaceuticals Call (AMAG)
Comtex SmarTrend(R) - Tue May 06, 11:06AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 6 months, AMAG Pharmaceuticals has returned 22.74% as of today's recent price of $18.67.
Shares of AMAG Down 24.7% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 29, 9:41AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 6 months, AMAG Pharmaceuticals has returned 24.73% as of today's recent price of $18.19.
Reported and Upcoming Financial Results, Upcoming Conference Participations, and US FDA Approval - Analyst Notes on AMAG, Insys Therapeutics, Cayman, Lannett and Magellan Health Services
PR Newswire - Tue Apr 29, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Insys Therapeutics, Inc. (NASDAQ: INSY), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), Lannett Company, Inc. (NYSE: LCI) and Magellan Health Services Inc. (NASDAQ: MGLN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1741-100free.
Study Showing Effectiveness of MuGard(R) for Management of Oral Mucositis Featured in the Journal Cancer
GlobeNewswire - Mon Apr 28, 7:01AM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that the publication of data from a multi-institutional trial of MuGard has been featured in the print edition of the journal Cancer, available today. MuGard is a mucoadhesive hydrogel that forms a protective coating over the oral mucosa. The randomized, double-blind, placebo-controlled trial showed MuGard was more effective than a sham-control in significantly reducing the mouth and throat soreness associated with oral mucositis, a common and debilitating side effect of radiotherapy used to treat patients with head and neck cancer.
Wider-than-Expected Q1 Loss at AMAG - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 10:00AM CDT
AMAG Pharmaceuticals Inc.'s (AMAG) first quarter 2014 loss of 33 cents per share was wider than the Zacks Consensus Estimate of a loss of 6 cents.
AMAG Pharmaceuticals' net loss widens to USD7.1m, but revenue up 17% in Q1 2014
M2 - Fri Apr 25, 4:37AM CDT
Pharmaceutical company AMAG Pharmaceuticals (NasdaqGS:AMAG) on Thursday reported a net loss of USD7.1m (USD0.33 per share) for the first quarter ended 31 March 2014.
AMAG Announces First Quarter 2014 Financial Results
GlobeNewswire - Thu Apr 24, 6:01AM CDT
17% Total Revenue Growth, Driven by Strong Feraheme Performance
Downtrend Call Working As AMAG Pharmaceuticals Stock Falls 23.9% (AMAG)
Comtex SmarTrend(R) - Tue Apr 22, 9:13AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 6 months, AMAG Pharmaceuticals has returned 23.86% as of today's recent price of $18.40.
AMAG Pharmaceuticals, Inc. to Host Conference Call on April 24, 2014 at 8:00 a.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2014
GlobeNewswire - Tue Apr 22, 7:00AM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced it will report unaudited consolidated financial results for the quarter ended March 31, 2014 before the U.S. financial markets open on Thursday, April 24, 2014. The announcement will be followed by a conference call and webcast with slides at 8:00 a.m. ET during which management will discuss the company's first quarter financial results and provide a business update, including commercial performance and other activities.
AMAG Pharmaceuticals Announces Appointment of Jim Sulat to Its Board of Directors and the Transition of Chairman Role to Gino Santini
GlobeNewswire - Wed Apr 16, 6:49PM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced new appointments to its board of directors. Current board member, Gino Santini, has been elected, by unanimous vote, to chairman of the board of directors, effective immediately, taking over for Mike Narachi. Mr. Narachi informed the board that, after eight years of service, he has decided not to stand for re-election at this year's upcoming annual shareholder meeting in May 2014. In addition, James R. Sulat has been elected to serve as a new member of the board of directors, effective immediately.
AMAG Pharmaceuticals Has Returned 28.6% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Mon Apr 14, 4:46PM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 5 months, AMAG Pharmaceuticals has returned 28.57% as of today's recent price of $17.26.
AMAG Pharmaceuticals Shares Down 25.1% Since SmarTrend's Sell Call (AMAG)
Comtex SmarTrend(R) - Mon Apr 07, 11:06AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 5 months, AMAG Pharmaceuticals has returned 25.10% as of today's recent price of $18.10.
AMAG Pharmaceuticals, Inc. to Present at the Needham Healthcare Conference
GlobeNewswire - Tue Apr 01, 4:00PM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the 13 Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 2:20 p.m. ET in New York. The session will include a company presentation followed by a question and answer session, in which the company's business and financial outlook, strategy and growth prospects will be discussed.
AMAG Pharmaceuticals Has Returned 13.7% Since SmarTrend Recommendation (AMAG)
Comtex SmarTrend(R) - Mon Mar 24, 9:27AM CDT
SmarTrend identified a Downtrend for AMAG Pharmaceuticals (NASDAQ:AMAG) on November 7th, 2013 at $24.17. In approximately 5 months, AMAG Pharmaceuticals has returned 13.72% as of today's recent price of $20.85.
Concise Analysis of the International Intravenous (IV) Iron Drugs Industry
M2 - Tue Mar 11, 5:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k8bxct/intravenous_iv) has announced the addition of the "Concise Analysis of the International Intravenous (IV) Iron Drugs Industry" report to their offering. This report analyzes the worldwide markets for Intravenous (IV) Iron Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 20 companies including many key and niche players such as: - Actavis, Inc. - AMAG Pharmaceuticals, Inc. - Fresenius Medical Care AG & Co. - KGaA Galenica Ltd. - Vifor Pharma Ltd. - Luitpold Pharmaceuticals, Inc. - American Regent, Inc. Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. For information on site licence pricing please click on Enquire before buying. Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Outlook 2. Industry Overview & Trends 3. Regulatory Overview 4. Overview Of Intravenous (Iv) Iron Drugs 5. Product Launches/Approvals 6. Recent Industry Activity 7. Focus On Select Players 8. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. Latin America 7. Rest Of World IV. Competitive Landscape Total Companies Profiled: 20 (including Divisions/Subsidiaries - 22) - The United States (
- Japan (2) - Europe (4) - Germany (1) - Rest of Europe (3) - Asia-Pacific (Excluding Japan) ( For more information visit http://www.researchandmarkets.com/research/k8...avenous_iv Stock Price Updates, Appointment, and Financial Results - Analyst Notes on Regeneron, DENTSPLY, AMAG, Cadence, and ArthroCare
PR Newswire - Thu Mar 06, 10:50AM CST
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), DENTSPLY International Inc. (NASDAQ: XRAY), AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Cadence Pharmaceuticals Inc. (NASDAQ: CADX), and ArthroCare Corporation (NASDAQ: ARTC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
